Business Wire

CURVE

25.5.2021 11:02:10 CEST | Business Wire | Press release

Share
Curve’s Eagerly Anticipated Crowdfund Goes Live

The highly anticipated crowdfunding round from Curve, the fast-growing financial super app, is live.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210525005099/en/

Prospective investors, including new and existing customers, can find the full details of the crowdfund live on Crowdcube’s website [http://www.crowdcube.com/curve ].

The launch of the crowdfunding round follows a highly popular pre-registration campaign, which allowed those who signed up to receive advance details of how to invest. In the first 24 hours of Curve’s announcement on May 11th of its intention to crowdfund, 21,000 individuals signed up to register their interest to invest in the limited number of shares on offer today.

Shachar Bialick, Founder and CEO of Curve, said: “Today’s the day for those who have followed our crowdfunding campaign closely to be able to invest and join in the next stage of our amazing journey. We’re customer obsessed, so it should come as no surprise that this campaign has been all about our customers. We simply wouldn’t be where we are without them, and I can’t wait to welcome a new wave of customers and supporters as shareholders in Curve. "

Curve launched the campaign to give its growing customer base an opportunity to share in its future success following the rapid growth it has seen recently. Since its record-breaking crowdfund in September 2019, Curve’s valuation has tripled to £591.7m. Between February 2020 and March 2021 Curve:

  • More than doubled its customer base to over 2 million
  • Expanded its workforce by over 100
  • Saw its gross transaction value grow to £2.6 billion

The proceeds of the crowdfunding round and its successful Series C round will be used to fuel the company’s international expansion and product innovation.

*The issuing of securities is subject to local laws and regulations, some of which place additional requirements on issuers. As a result, Curve has decided to restrict its offer of securities in certain EEA countries. Full details are available on Curve’s pitch page on Crowdcube’s website (see link above).

ENDS

About Curve

Curve is an all in one financial super app. Its mission is to be a one-stop shop for all the financial needs of a consumer; a single point of access to a wide range of financial products and services, bundling together all your money into one smart card and an even smarter app. Unlike other services available in the market today, Curve allows customers to connect and supercharge their legacy banks to the 21st century, without leaving their bank or signing up to a new bank. Curve is live in 31 markets across the UK and European Economic Area (EEA).

Curve provides a host of benefits to its customers:

  • Combines a customer’s Mastercard and Visa debit and credit cards in one card.
  • Enables customers’ cards to fit into Apple Pay, Google Pay, Samsung Pay, FitBit Pay and many more, even if their banks do not support this integration.
  • Curve provides 1% cash back on selected retailers for the first 30 days, or for an unlimited time on Curve’s paid subscriptions.
  • With Curve’s patented Go-Back-In-Time® feature, Curve customers may be able to swap their spend to a different account, up to 90 days after the purchase was made.
  • Increased security and privacy - Curve simplifies customers’ lives by providing them with only one pin to remember; keeping other sensitive card numbers safe by using Curve when spending online; providing real time spending notifications and the ability to lock the Curve card directly from the app.
  • Peace of mind - Curve’s premium Metal offering provides mobile phone insurance and travel insurance to ensure customers can focus on living their lives, rather than worrying about losing their phone or bags when they travel.

Curve supports Mastercard and Visa networks. The Curve Card and e-money, related to cards issued in the UK, is issued by Curve OS Limited, authorised in the UK by the Financial Conduct Authority to issue electronic money (firm reference number 900926). The Curve Card and e-money, related to cards issued in the EEA, is issued by Curve Europe UAB, authorised in Lithuania by the Bank of Lithuania (electronic money institution license No. 73 issued on 22 of October, 2020).

For more information go to www.curve.com , like our Facebook page and follow us on LinkedIn , Twitter @imaginecurve and Instagram @imaginecurve .

About the crowdfund

This announcement is not an offer of securities for sale or subscription in any jurisdiction, and should not be relied upon in connection with any offer. Any investment decision should be based solely on the basis of the terms of the investment, which will be made available to eligible potential investors in due course.

Not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the USA, Canada, and Japan or any other state or jurisdiction in which such release, publication or distribution would be unlawful.

Investing involves risk and should be done only as part of a diversified portfolio. Investing equity in start-ups and early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution. Crowdcube is targeted exclusively at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. Approved as a financial promotion by Crowdcube Capital Limited which is authorised and regulated by the Financial Conduct Authority (No. 650205).

END

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye